Nieuws en video's - PHARMING GROUP - Pagina 2

Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of May: H.C. Wainwright 2 nd Annual BioConnect Investor Conference at NASDAQ, New York, May 20, 2024 Michael Levitan, VP Investor Relations and Corporate Communications will present on Monday, May 20 at 09:30 EDT/15:30 CET. For more information about this conference, or to...

THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 15 May 2024: Pharming...

First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023 Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023 On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth) Overall cash and marketable...

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and...

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare...

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 19 th April, 2024: Pharming Group N.V. (" Pharming " or the " Company ") (Euronext Amsterdam: PHARM) announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds due 2025 issued...

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18 th April, 2024: Pharming Group N.V. (" Pharming " or the " Company ") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “ New Bonds ”) convertible into new and/or existing ordinary shares in the...

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18 th April, 2024: Pharming Group N.V. (" Pharming " or the "...

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial ( NCT05438407 ) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in...

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The agenda of the AGM includes the reappointment...

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2023 Annual...

Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April: 23rd Annual Needham Virtual Healthcare Conference, April 8-11, 2024 Sijmen de Vries, Chief Executive Officer, will present on Monday, April 8 at 8:45ET/14:45CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and...

Full year 2023 total revenues increased by 19% to US$245.3 million Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million Strong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 million Overall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end...

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024. To participate in the conference call, please register in advance using the link below. Once registered,...

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of February: Oppenheimer 34 th Annual Healthcare Life Sciences Virtual Conference, February 13-14, 2024 Sijmen de Vries, Chief Executive Officer, will present on Tuesday, February 13 at 11:20 ET/17:20 CET. A live webcast and replay of the presentation will be available in...

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the...

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2 Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming has...

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral,...

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on...

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November: Stifel 2023 Healthcare Conference, New York, November 14-15 Anurag Relan, Chief Medical Officer will participate in a fireside chat, question and answer session on Tuesday, November 14 at 08:35 am ET/14:35 CET. Jefferies London Healthcare Conference 2023,...